{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T05:13:03Z","timestamp":1739941983070,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"DOI":"10.7759\/cureus.79207","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:45:22Z","timestamp":1739875522000},"source":"Crossref","is-referenced-by-count":0,"title":["The Possibility of Ceftolozane\/Tazobactam-Resistant Pseudomonas aeruginosa Emergence After Two Days of Antibiotic Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Yoshihide","family":"Hioki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazufumi","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac184","article-title":"Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial","volume":"77","author":"Paterson DL","year":"2022","unstructured":"Paterson DL, Bassetti M, Motyl M, et al.. Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. J Antimicrob Chemother. 2022, 77:2522-31. 10.1093\/jac\/dkac184","journal-title":"J Antimicrob Chemother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-024-01291-5","article-title":"Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis","volume":"14","author":"Luque Paz D","year":"2024","unstructured":"Luque Paz D, Chean D, Tattevin P, et al.. Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis. Ann Intensive Care. 2024, 14:66. 10.1186\/s13613-024-01291-5","journal-title":"Ann Intensive Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef MH","year":"2019","unstructured":"Kollef MH, Nov\u00e1\u010dek M, Kivistik \u00dc, et al.. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. The Lancet Infectious diseases. 2019, 19:1299-311. 10.1016\/s1473-3099(19)30403-7","journal-title":"The Lancet Infectious diseases"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106278","article-title":"Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)","volume":"57","author":"Johnson MG","year":"2021","unstructured":"Johnson MG, Bruno C, Castanheira M, et al.. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). Int J Antimicrob Agents. 2021, 57:106278. 10.1016\/j.ijantimicag.2021.106278","journal-title":"Int J Antimicrob Agents"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01669-23","article-title":"Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan","volume":"68","author":"Yano H","year":"2024","unstructured":"Yano H, Hayashi W, Kawakami S, et al.. Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan. Antimicrob Agents Chemother. 2024, 68:e0166923. 10.1128\/aac.01669-23","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group","volume":"30","author":"Oliver A","year":"2024","unstructured":"Oliver A, Rojo-Molinero E, Arca-Suarez J, et al.. Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group. Clin Microbiol Infect. 2024, 30:469-80. 10.1016\/j.cmi.2023.12.026","journal-title":"Clin Microbiol Infect"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda S","year":"2007","unstructured":"Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007, 51:826-30. 10.1128\/AAC.00860-06","journal-title":"Antimicrob Agents Chemother"},{"key":"ref8","unstructured":"Institute CaLS. performance standards for antimicrobial susceptibility testing. In CLSI supplement M100, 34rd. (2024). https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1212-7","article-title":"Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"23","author":"Balke B","year":"2004","unstructured":"Balke B, Hoy L, Weissbrodt H, H\u00e4ussler S. Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2004, 23:765-71. 10.1007\/s10096-004-1212-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref10","article-title":"Manual of clinical microbiology, 13th ed.","year":"2023","unstructured":"Manual of clinical microbiology, 13th ed.. Carroll KC PM, Karlowsky JA, Landry ML, McAdam AJ, Patel R, Pritt BS (ed). ASM Press, Washington, DC; 2023."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jam.13016","article-title":"Applying a PCR-based open-reading frame typing method for easy genotyping and molecular epidemiological analysis of Pseudomonas aeruginosa","volume":"120","author":"Suzuki M","year":"2016","unstructured":"Suzuki M, Yamada K, Aoki M, Hosoba E, Matsumoto M, Baba H, Iinuma Y. Applying a PCR-based open-reading frame typing method for easy genotyping and molecular epidemiological analysis of Pseudomonas aeruginosa. J Appl Microbiol. 2016, 120:487-97. 10.1111\/jam.13016","journal-title":"J Appl Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.06.014","article-title":"Clonality investigation of clinical Escherichia coli isolates by polymerase chain reaction-based open-reading frame typing method","volume":"26","author":"Saeki M","year":"2020","unstructured":"Saeki M, Sato T, Furuya D, et al.. Clonality investigation of clinical Escherichia coli isolates by polymerase chain reaction-based open-reading frame typing method. J Infect Chemother. 2020, 26:38-42. 10.1016\/j.jiac.2019.06.014","journal-title":"J Infect Chemother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2017.10.023","article-title":"Molecular typing of methicillin-resistant Staphylococcus aureus: comparison of PCR-based open reading frame typing, multilocus sequence typing, and Staphylococcus protein A gene typing","volume":"24","author":"Ogihara S","year":"2018","unstructured":"Ogihara S, Saito R, Sawabe E, et al.. Molecular typing of methicillin-resistant Staphylococcus aureus: comparison of PCR-based open reading frame typing, multilocus sequence typing, and Staphylococcus protein A gene typing. J Infect Chemother. 2018, 24:312-4. 10.1016\/j.jiac.2017.10.023","journal-title":"J Infect Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02291-19","article-title":"Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections","volume":"64","author":"Jorgensen SC","year":"2020","unstructured":"Jorgensen SC, Trinh TD, Zasowski EJ, et al.. Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections. Antimicrob Agents Chemother. 2020, 64:10.1128\/AAC.02291-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2231","article-title":"Antimicrobial susceptibility of coagulase-negative staphylococci","volume":"38","author":"Archer GL","year":"1994","unstructured":"Archer GL, Climo MW. Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrob Agents Chemother. 1994, 38:2231-7. 10.1128\/AAC.38.10.2231","journal-title":"Antimicrob Agents Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010449","article-title":"Antibiotic heteroresistance in Klebsiella pneumoniae","volume":"23","author":"Stojowska-Sw\u0119drzy\u0144ska K","year":"2021","unstructured":"Stojowska-Sw\u0119drzy\u0144ska K, \u0141upkowska A, Kuczy\u0144ska-Wi\u015bnik D, Laskowska E. Antibiotic heteroresistance in Klebsiella pneumoniae. Int J Mol Sci. 2021, 23:10.3390\/ijms23010449","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0218-1","article-title":"Mechanisms and clinical relevance of bacterial heteroresistance","volume":"17","author":"Andersson DI","year":"2019","unstructured":"Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat Rev Microbiol. 2019, 17:479-96. 10.1038\/s41579-019-0218-1","journal-title":"Nat Rev Microbiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad083","article-title":"Ceftolozane\/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections","volume":"5","author":"Monogue ML","year":"2023","unstructured":"Monogue ML, Sanders JM, Pybus CA, Kim J, Zhan X, Clark AE, Greenberg DE. Ceftolozane\/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections. JAC Antimicrob Resist. 2023, 5:dlad083. 10.1093\/jacamr\/dlad083","journal-title":"JAC Antimicrob Resist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/339760-the-possibility-of-ceftolozanetazobactam-resistant-pseudomonas-aeruginosa-emergence-after-two-days-of-antibiotic-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T10:45:24Z","timestamp":1739875524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/339760-the-possibility-of-ceftolozanetazobactam-resistant-pseudomonas-aeruginosa-emergence-after-two-days-of-antibiotic-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.79207","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,18]]}}}